A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction.
作者信息
King S Bruce
机构信息
Department of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, USA.
出版信息
J Clin Invest. 2003 Jan;111(2):171-2. doi: 10.1172/JCI17597.
Abstract
摘要
相似文献
1
A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction.
J Clin Invest. 2003 Jan;111(2):171-2. doi: 10.1172/JCI17597.
2
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.
J Clin Invest. 2003 Jan;111(2):231-9. doi: 10.1172/JCI16672.
3
Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway.
Blood. 2004 May 15;103(10):3945-50. doi: 10.1182/blood-2003-08-2969. Epub 2004 Feb 5.
4
Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells.
Exp Hematol. 2006 Sep;34(9):1151-61. doi: 10.1016/j.exphem.2006.03.018.
5
[NO, a hormonally active substance].
Med Monatsschr Pharm. 1990 Mar;13(3):74-81.
6
[Guanylate cyclases: physiological processes mediated by cyclic GMP].
Nefrologia. 2001 May-Jun;21(3):233-9.
7
Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.
Br J Pharmacol. 1999 Nov;128(5):1082-8. doi: 10.1038/sj.bjp.0702874.
8
[Nitric oxide. The role of guanylate cyclase in its physiological effects].
Vopr Med Khim. 2002 Jan-Feb;48(1):4-30.
9
EDRF is an intracellular second messenger and autacoid to regulate cyclic GMP synthesis in many cells.
Adv Second Messenger Phosphoprotein Res. 1990;24:441-8.
10
Role of soluble guanylate cyclase in the molecular mechanism underlying the physiological effects of nitric oxide.
Biochemistry (Mosc). 1998 Jul;63(7):794-801.
引用本文的文献
1
Therapeutics for sickle cell disease intravascular hemolysis.
Front Physiol. 2024 Sep 13;15:1474569. doi: 10.3389/fphys.2024.1474569. eCollection 2024.
2
Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.
Clin Pharmacol Ther. 2021 Jan;109(1):73-81. doi: 10.1002/cpt.2028. Epub 2020 Oct 8.
3
Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies.
J Clin Med. 2019 Nov 9;8(11):1927. doi: 10.3390/jcm8111927.
4
Stroke in a Child with Hemoglobin SC Disease: A Case Report Describing use of Hydroxyurea after Transfusion Therapy.
Pediatr Rep. 2017 Mar 22;9(1):6984. doi: 10.4081/pr.2017.6984.
5
Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease.
Exp Biol Med (Maywood). 2015 Aug;240(8):1050-64. doi: 10.1177/1535370215596859.
6
Regulation of γ-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway.
Blood Cells Mol Dis. 2011 Jun 15;47(1):12-22. doi: 10.1016/j.bcmd.2011.03.003. Epub 2011 Apr 15.
7
Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation.
Exp Biol Med (Maywood). 2009 Nov;234(11):1374-82. doi: 10.3181/0811-RM-339. Epub 2009 Aug 5.
8
Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
Int J Environ Res Public Health. 2009 Mar;6(3):1124-44. doi: 10.3390/ijerph6031124. Epub 2009 Mar 16.
本文引用的文献
1
HYDROXYUREA: MECHANISM OF ACTION.
Science. 1963 Nov 22;142(3595):1069-70. doi: 10.1126/science.142.3595.1069.
2
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.
J Clin Invest. 2003 Jan;111(2):231-9. doi: 10.1172/JCI16672.
3
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.
Nat Med. 2002 Dec;8(12):1383-9. doi: 10.1038/nm1202-799. Epub 2002 Nov 11.
4
Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea.
J Am Chem Soc. 2002 Apr 3;124(13):3473-80. doi: 10.1021/ja012271v.
5
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.
Br J Haematol. 2002 Feb;116(2):436-44. doi: 10.1046/j.1365-2141.2002.03274.x.
6
Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea.
Biochemistry. 2002 Feb 19;41(7):2466-74. doi: 10.1021/bi011470o.
7
Nitric oxide therapy in sickle cell disease.
Semin Hematol. 2001 Oct;38(4):333-42. doi: 10.1016/s0037-1963(01)90027-7.
8
Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy.
Hematology. 2000;5(4):335-339. doi: 10.1080/10245332.2000.11746528.
9
Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway.
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1847-52. doi: 10.1073/pnas.98.4.1847. Epub 2001 Feb 6.
10
Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea.
Mol Pharmacol. 1999 Jun;55(6):1006-10. doi: 10.1124/mol.55.6.1006.
Zotero 插件